The digestibility of fucosylated glycosaminoglycan (FG) and its effects on digestive enzymes were investigated using an in vitro digestion model. Results showed that the molecular weight and the reducing sugar content of FG were not significantly changed, and no free monosaccharides released from FG were detected after the salivary, gastric and intestinal digestion, indicating that both the backbone and the sulfated fucose branches of FG are resistant to be cleaved in the saliva and gastrointestinal tract environments. Furthermore, FG can dose-dependently inhibit digestive enzymes such as α-amylase, pepsin and pancreatic lipase in different degrees under the simulated digestion conditions due to the sulfate and carboxyl groups. These physiological effects of FG may help control the postprandial glucose concentration and have the potential in the prevention or treatment of reflux disease and obesity. The findings may provide information on the digestibility and beneficial physiological effects of FG as a potential natural product to promote human health.
Keywords: 1-phenyl-3-methyl-5-pyrazolone (PubChem CID: 90474051); Acarbose hydrate (PubChem CID: 129837378); Alpha-d-glucose (PubChem CID: 79025); Digestive enzyme; Fucosylated glycosaminoglycan; Heparin (PubChem CID: 772); In vitro digestion; N-Acetyl-d-Galactosamine (PubChem CID: 35717); Orlistat (PubChem CID: 3034010); Polysaccharide; Sea cucumber; Sodium Alginate (PubChem CID: 5102882); d-Galactose (PubChem CID: 6036); d-Glucuronic acid (PubChem CID: 94715); l-Fucose (PubChem CID: 17106).
Copyright © 2018 Elsevier Ltd. All rights reserved.